A report by Transparency Market Research uncovers after in-depth
study that the global rheumatology therapeutics market will rise at a
lackluster CAGR of 2.7% from 2017 to 2025 to become worth US$ 52.96
bn by 2025 from US$41.88 bn in 2016.
The various drug classes in the global rheumatology therapeutics
market are disease modifying anti-rheumatic drugs (DMARDs),
non-steroidal anti-inflammatory drugs (NSAID’s), corticosteroids,
uric acid drugs, etc. The DMARDs, which is a group of medicines or
combination of medicines used to treat rheumatic diseases by blocking
the inflammation, accounts for maximum share in the market at
present. They are categorized into two major types - biologic DMARDs
and synthetic DMARDs. By rising at a 2.6% CAGR from 2017 to 2025 the
segment is expected to retain its dominant share in the upcoming
years.
Geographically, the key segments of the global rheumatology
therapeutics market are North America, South America, Europe, Asia
Pacific, and the Middle East and Africa. Of them, North America leads
the market with dominant share on account of a burgeoning geriatric
population highly susceptible to various kinds of rheumatology
disorders. Further, uptake of biologics and biosimilar products for
treating moderate to severe rheumatoid arthritis and superior
healthcare facilities has also proved beneficial to the market in the
region.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1494
Rheumatology is the multidisciplinary approach towards the diagnosis
and treatment of the various rheumatic disease which includes
clinical problems in joints, soft tissues, heritable connective
tissue disorders, vasculitis, and autoimmune diseases. Rheumatic
disease is associated with inflammation that affects the bones,
tendons, ligaments, and sometimes organs.
At the forefront of driving growth in the global rheumatology
therapeutics market is the ever-increasing elderly population
worldwide and swift approval of new drugs for treating various
rheumatic diseases. In August 2017, for example, the FDA approved
DUZALLO drug by Ironwood Pharmaceuticals, Inc. and AstraZeneca. It is
the first and only therapy that leverages two types of mechanisms in
gout with only one pill. Again, in 2017, Kevzara (Sanofi and
Regeneron Pharmaceuticals, Inc.) got the FDA approval to treat adult
patients with moderately to severely active rheumatoid arthritis
(RA). In 2017, AbbVie Inc., a global leader in anti-rheumatic drugs,
announced its four potential candidates, which are Upadacitinib,
Risankizumab, ABBV-599, and ABT-981, that are in different phases of
clinical trials to treat conditions such as rheumatoid arthritis,
psoriatic arthritis, and osteoarthritis (OA).
Download Report Brochure @
Other factors positively influencing the market are rising knowledge
among people about rheumatic diseases and emergence of cost-effective
rheumatology therapeutics. Further, increasing investment in research
and development is likely to bolster the growth of global
rheumatology therapeutics market during the forecast period.
Prominent companies operating in the global rheumatology therapeutics
market are AbbVie, Inc., Pfizer, Inc., Bristol-Myers Squibb Company,
Merck & Co., Inc. etc. Some other key players in the market are
Amgen, Inc., Janssen Biotech, Inc., Novartis AG, Genentech, Inc.,
Sanofi, and Takeda Pharmaceutical.
Purchase this Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=1494<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment